Literature DB >> 16550383

Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease.

Takashi Kawachi1, Kazunari Ishii, Setsu Sakamoto, Masahiro Sasaki, Tetsuya Mori, Fumio Yamashita, Hiroshi Matsuda, Etsuro Mori.   

Abstract

PURPOSE: The aim of this study was to compare the diagnostic performance of( 18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) and voxel-based morphometry (VBM) on magnetic resonance imaging (MRI) in the same group of patients with very mild Alzheimer's disease (AD).
METHODS: Thirty patients with very mild AD (age 67.0+/-5.8 years; MMSE score 25.5+/-1.2, range 24-28), 32 patients with mild AD (age 67.0+/-4.5 years, MMSE score 22.1+/-0.8, range 21-23) and 60 age- and sex-matched normal volunteers underwent both FDG-PET and three-dimensional spoiled gradient echo MRI. Statistical parametric mapping was used to conduct voxel by voxel analysis and Z score mapping. First, the region of interest (ROI) maps of significant reductions in glucose metabolism and grey matter density in the mild AD patients were defined. Secondly, analysis of receiver operating characteristic (ROC) curves for Z scores in the ROI maps discriminating very mild AD patients and normal controls was performed.
RESULTS: In mild AD patients, FDG-PET indicated significant reductions in glucose metabolism in the bilateral posterior cingulate gyri and the right parietotemporal area, while VBM analysis showed a significant decrease in grey matter volume density in the bilateral amygdala/hippocampus complex, compared with the normal control group. ROC analysis showed that in very mild AD patients the accuracy of FDG-PET diagnosis was 89% and that of VBM-MRI diagnosis was 83%. The accuracy of the combination of FDG-PET and VBM-MRI diagnosis was 94%.
CONCLUSION: In very mild AD, both FDG-PET and VBM-MRI had high accuracy for diagnosis, but FDG-PET showed slightly higher accuracy than VBM-MRI. Combination of the two techniques will yield a higher diagnostic accuracy in very mild AD by making full use of functional and morphological images.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16550383     DOI: 10.1007/s00259-005-0050-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  40 in total

1.  Comparison of gray matter and metabolic reduction in mild Alzheimer's disease using FDG-PET and voxel-based morphometric MR studies.

Authors:  Kazunari Ishii; Hiroki Sasaki; Atsushi K Kono; Naokazu Miyamoto; Tetsuya Fukuda; Etsuro Mori
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-31       Impact factor: 9.236

2.  Frontal lobe hypometabolism and depression in Alzheimer's disease.

Authors:  N Hirono; E Mori; K Ishii; Y Ikejiri; T Imamura; T Shimomura; M Hashimoto; H Yamashita; M Sasaki
Journal:  Neurology       Date:  1998-02       Impact factor: 9.910

3.  Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections.

Authors:  J H Burdette; S Minoshima; T Vander Borght; D D Tran; D E Kuhl
Journal:  Radiology       Date:  1996-03       Impact factor: 11.105

4.  The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation.

Authors:  M J de Leon; J Golomb; A E George; A Convit; C Y Tarshish; T McRae; S De Santi; G Smith; S H Ferris; M Noz
Journal:  AJNR Am J Neuroradiol       Date:  1993 Jul-Aug       Impact factor: 3.825

5.  Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry.

Authors:  E J Burton; G Karas; S M Paling; R Barber; E D Williams; C G Ballard; I G McKeith; P Scheltens; F Barkhof; J T O'Brien
Journal:  Neuroimage       Date:  2002-10       Impact factor: 6.556

6.  Voxel-based morphometric comparison between early- and late-onset mild Alzheimer's disease and assessment of diagnostic performance of z score images.

Authors:  Kazunari Ishii; Takashi Kawachi; Hiroki Sasaki; Atsushi K Kono; Tetsuya Fukuda; Yoshio Kojima; Etsuro Mori
Journal:  AJNR Am J Neuroradiol       Date:  2005-02       Impact factor: 3.825

7.  Amygdalohippocampal MR volume measurements in the early stages of Alzheimer disease.

Authors:  S Lehéricy; M Baulac; J Chiras; L Piérot; N Martin; B Pillon; B Deweer; B Dubois; C Marsault
Journal:  AJNR Am J Neuroradiol       Date:  1994-05       Impact factor: 3.825

8.  Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer's disease.

Authors:  J P Kesslak; O Nalcioglu; C W Cotman
Journal:  Neurology       Date:  1991-01       Impact factor: 9.910

9.  Alteration of regional cerebral glucose utilization with delusions in Alzheimer's disease.

Authors:  N Hirono; E Mori; K Ishii; H Kitagaki; M Sasaki; Y Ikejiri; T Imamura; T Shimomura; M Ikeda; H Yamashita
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1998       Impact factor: 2.198

10.  MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET.

Authors:  L Mosconi; D Perani; S Sorbi; K Herholz; B Nacmias; V Holthoff; E Salmon; J-C Baron; M T R De Cristofaro; A Padovani; B Borroni; M Franceschi; L Bracco; A Pupi
Journal:  Neurology       Date:  2004-12-28       Impact factor: 9.910

View more
  33 in total

1.  Automatic voxel-based morphometry of structural MRI by SPM8 plus diffeomorphic anatomic registration through exponentiated lie algebra improves the diagnosis of probable Alzheimer Disease.

Authors:  H Matsuda; S Mizumura; K Nemoto; F Yamashita; E Imabayashi; N Sato; T Asada
Journal:  AJNR Am J Neuroradiol       Date:  2012-02-02       Impact factor: 3.825

2.  Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease.

Authors:  David S Karow; Linda K McEvoy; Christine Fennema-Notestine; Donald J Hagler; Robin G Jennings; James B Brewer; Carl K Hoh; Anders M Dale
Journal:  Radiology       Date:  2010-09       Impact factor: 11.105

3.  Structural and functional biomarkers of prodromal Alzheimer's disease: a high-dimensional pattern classification study.

Authors:  Yong Fan; Susan M Resnick; Xiaoying Wu; Christos Davatzikos
Journal:  Neuroimage       Date:  2008-03-06       Impact factor: 6.556

4.  Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process.

Authors:  Rafael González-Redondo; David García-García; Pedro Clavero; Carmen Gasca-Salas; Reyes García-Eulate; José L Zubieta; Javier Arbizu; José A Obeso; María C Rodríguez-Oroz
Journal:  Brain       Date:  2014-06-20       Impact factor: 13.501

5.  Whither the hippocampus? FDG-PET hippocampal hypometabolism in Alzheimer disease revisited.

Authors:  J A Maldjian; C T Whitlow
Journal:  AJNR Am J Neuroradiol       Date:  2012-06-14       Impact factor: 3.825

6.  Feed-forward hierarchical model of the ventral visual stream applied to functional brain image classification.

Authors:  David B Keator; James H Fallon; Anita Lakatos; Charless C Fowlkes; Steven G Potkin; Alexander Ihler
Journal:  Hum Brain Mapp       Date:  2012-07-30       Impact factor: 5.038

7.  Role of structural MRI in Alzheimer's disease.

Authors:  Prashanthi Vemuri; Clifford R Jack
Journal:  Alzheimers Res Ther       Date:  2010-08-31       Impact factor: 6.982

8.  Functional brain imaging: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-12-01

9.  Distinct MRI atrophy patterns in autopsy-proven Alzheimer's disease and frontotemporal lobar degeneration.

Authors:  G D Rabinovici; W W Seeley; E J Kim; M L Gorno-Tempini; K Rascovsky; T A Pagliaro; S C Allison; C Halabi; J H Kramer; J K Johnson; M W Weiner; M S Forman; J Q Trojanowski; S J Dearmond; B L Miller; H J Rosen
Journal:  Am J Alzheimers Dis Other Demen       Date:  2007 Dec-2008 Jan       Impact factor: 2.035

10.  Comparison between MRI-based attenuation correction methods for brain PET in dementia patients.

Authors:  Jorge Cabello; Mathias Lukas; Elena Rota Kops; André Ribeiro; N Jon Shah; Igor Yakushev; Thomas Pyka; Stephan G Nekolla; Sibylle I Ziegler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-20       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.